Altamira Therapeutics Future Growth
Future criteria checks 0/6
Altamira Therapeutics's earnings are forecast to decline at 5.9% per annum while its annual revenue is expected to grow at 149% per year. EPS is expected to grow by 78.9% per annum.
Key information
-5.9%
Earnings growth rate
78.9%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 149.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7 | -9 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -13 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -11 | N/A | N/A | 1 |
| 6/30/2024 | N/A | -8 | -8 | -8 | N/A |
| 3/31/2024 | N/A | -8 | -10 | -10 | N/A |
| 12/31/2023 | N/A | -9 | -14 | -14 | N/A |
| 6/30/2023 | 0 | -26 | -13 | -12 | N/A |
| 3/31/2023 | 0 | -27 | -12 | -11 | N/A |
| 12/31/2022 | N/A | -20 | -12 | -9 | N/A |
| 9/30/2022 | 0 | -23 | -14 | -12 | N/A |
| 6/30/2022 | 0 | -19 | -18 | -15 | N/A |
| 3/31/2022 | 0 | -19 | -19 | -15 | N/A |
| 12/31/2021 | N/A | -7 | -19 | -15 | N/A |
| 9/30/2021 | 0 | -16 | -15 | -12 | N/A |
| 6/30/2021 | N/A | -13 | -13 | -9 | N/A |
| 3/31/2021 | N/A | -11 | -10 | -7 | N/A |
| 12/31/2020 | N/A | -9 | -8 | -5 | N/A |
| 9/30/2020 | N/A | -8 | -8 | -5 | N/A |
| 6/30/2020 | N/A | -6 | -7 | -5 | N/A |
| 3/31/2020 | N/A | -6 | -10 | -7 | N/A |
| 12/31/2019 | N/A | -7 | -12 | -9 | N/A |
| 9/30/2019 | N/A | -9 | -13 | -9 | N/A |
| 6/30/2019 | N/A | -11 | -15 | -11 | N/A |
| 3/31/2019 | N/A | -12 | -14 | -11 | N/A |
| 12/31/2018 | N/A | -12 | -15 | -13 | N/A |
| 9/30/2018 | N/A | -13 | -18 | -18 | N/A |
| 6/30/2018 | N/A | -16 | -19 | -19 | N/A |
| 3/31/2018 | N/A | -19 | N/A | -24 | N/A |
| 12/31/2017 | N/A | -25 | N/A | -25 | N/A |
| 9/30/2017 | N/A | -26 | N/A | -25 | N/A |
| 6/30/2017 | N/A | -28 | N/A | -27 | N/A |
| 3/31/2017 | N/A | -30 | N/A | -29 | N/A |
| 12/31/2016 | N/A | -30 | N/A | -29 | N/A |
| 9/30/2016 | N/A | -32 | N/A | -31 | N/A |
| 6/30/2016 | N/A | -29 | N/A | -31 | N/A |
| 3/31/2016 | N/A | -32 | N/A | -31 | N/A |
| 12/31/2015 | N/A | -30 | N/A | -29 | N/A |
| 9/30/2015 | N/A | -29 | N/A | -28 | N/A |
| 6/30/2015 | N/A | -28 | N/A | -24 | N/A |
| 3/31/2015 | N/A | -21 | N/A | -22 | N/A |
| 12/31/2014 | N/A | -18 | N/A | -19 | N/A |
| 9/30/2014 | N/A | -19 | N/A | -19 | N/A |
| 6/30/2014 | N/A | -21 | N/A | -22 | N/A |
| 3/31/2014 | N/A | -21 | N/A | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYTO.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYTO.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYTO.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYTO.F is forecast to have no revenue next year.
High Growth Revenue: CYTO.F is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYTO.F's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Altamira Therapeutics Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Maxim Jacobs | Edison Investment Research |
| Christopher Howerton | Jefferies LLC |